MedTrace Logo

Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer

NCT04830813 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2024-12-09

No results posted yet for this study

Summary

Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.

Conditions

Interventions

DRUG

Chiauranib

Patients take Chiauranib capsules 50mg, orally once daily, 21 days as a cycle until objective disease progression.

DRUG

Placebo

Participants received Chiauranib placebo capsule matching Chiauranib orally once daily until objective disease progression.

Sponsors & Collaborators

  • Chipscreen Biosciences, Ltd.

    lead INDUSTRY

Principal Investigators

  • Yuankai Shi · Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-05
Primary Completion
2024-04-01
Completion
2024-04-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04830813 on ClinicalTrials.gov